Inhibitory effect of modified citrus pectin on liver metastases in a mouse colon cancer model

Abstract

and MCP treatment groups was significantly higher than that in the negative control group. However, there was no significant difference between them. Except for the negative control group, the expression of galectin-3 in liver metastases of the other 4 groups showed no significant difference. CONCLUSION: Expression of galectin-3 increases significantly in liver metastasis of colon cancer, which can be effectively inhibited by MCP.

Plant Pectin: A Potential Source for Cancer Suppression

“…The results showed only 50% of the rats that drank water with MCP (0.1% weight/volume) had any metastases, while 94% of the rats that drank plain water had cancer metastasize to their lungs. Similarly, several animal studies have found that MCP helps reduce the spread of not only prostate cancer but also breast, skin and liver cancer (Nangia-Makker et al, 2002;Platt and Raz, 1992;Liu et al, 2008). MCP was fed to mice with these types of cancer and the mice were found to have a much lower chance of the tumor spreading to the lungs.…”

Hyaluronan–cisplatin conjugate nanoparticles embedded in Eudragit S100-coated pectin/alginate microbeads for colon drug delivery

“…In addition, Liu et al demonstrated that pectin could target tumor cells by binding to the galectin-3 receptor to inhibit cancer progression and metastasis. 12 Pectin consists mainly of linear chains of α-(1-4)-D-galacturonic acid with varying degrees of esterification. The broad molecular weight distribution is due to the main linear chain being partly interrupted by other neutral sugars.…”

Regulation of Ras signaling and function by plasma membrane microdomains

“…Gal-3-mediated KRAS activation is associated with ERK, but not PI3K, signaling (48). There is substantial evidence for Gal-3 inhibition as a potential tumor blocker (183)(184)(185)(186)(187)(188)(189)(190) Predicted effects of dual inhibition of Galectin-3, and mTOR (rapamycin or other mTOR inhibitors), in KRAS mutant tumors. Gal-3 inhibition reduces KRAS membrane anchorage, greatly reducing Raf activation which is lipid ordered domain-restricted, but allowing PI3K activation which is distributed across membrane microdomains.…”